DEXCOM INC
For the period ended Dec 31, 2025. Filed Feb 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 12, 2026
DXCM$81.07+2.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Schedule II – Valuation and Qualifying Accounts
DexCom, Inc.
SCHEDULE II – VALUATION AND QUALIFYING ACCOUNTS
(In millions)
| Twelve Months EndedDecember 31, | |||
|---|---|---|---|
| Allowance for doubtful accounts | 2025 | 2024 | 2023 |
| Beginning Balance | $9.2 | $9.3 | $7.3 |
| Provision for doubtful accounts | 3.3 | (0.1) | 2.0 |
| Write-offs and adjustments | — | — | — |
| Recoveries | — | — | — |
| Ending Balance | $12.5 | $9.2 | $9.3 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.